Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy

References

• Lichtenstein AK, Levine A, Taylor CR, et al. Primary mediastinal lymphoma in adults. Am J Med 1980;68:509–514.
   PubMed Web of Science ®Google Scholar
• Gaulard P, Harris NL, Pileri SA, et al. Primary mediastinal (thymic) large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, et al. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. pp 250–251.
   Google Scholar
• Cazals-Hatem D, Lepage E, Brice P, et al. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (Groupe d’Etude des Lymphomes de l’Adulte) study. Am J Surg Pathol 1996;20:877–888.
   PubMed Web of Science ®Google Scholar
• Rieger M, Osterborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol 2011;22:664–670.
   PubMed Web of Science ®Google Scholar
• Tai WM, Quah D, Yap SP, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive Asian patients. Leuk Lymphoma 2011;52:604–612.
   PubMed Web of Science ®Google Scholar
• Lazzarino M, Orlandi E, Paulli M, et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol 1997;15:1646–1653.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006;17:123–130.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Martelli M, Magagnoli M, et al. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by 67gallium scan in 50 patients. Blood 1999;94:3289–3293.
   PubMed Web of Science ®Google Scholar
• Todeschini G, Secchi S, Morra E, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004;90:372–376.
   PubMed Web of Science ®Google Scholar
• Jacobson JO, Aisenberg AC, Lamarre L, et al. Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy. Cancer 1988;62:1893–1898.
   PubMed Web of Science ®Google Scholar
• Hamlin PA, Portlock CS, Straus DJ, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol 2005;130:691–699.
   PubMed Web of Science ®Google Scholar
• Martelli MP, Martelli M, Pescarmona E, et al. MACOP-B and involved field radiation therapy is an effective therapy for primary mediastinal large B-cell lymphoma with sclerosis. Ann Oncol 1998; 9:1027–1029.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Martelli M, Bertini M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica 2002;87:1258–1264.
   PubMed Web of Science ®Google Scholar
• Sun A, Tsang M, Pintilie M, et al. Combined modality therapy for clinical stage I and II primary mediastinal large B-cell lymphoma treated at the Princess Margaret Hospital. Int J Radiat Oncol Biol Phys 2002;54:298–299.
   Google Scholar
• Mazzarotto R, Boso C, Vianello F, et al. Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients. A single institution experience. Int J Radiat Oncol Biol Phys 2007;68:823–829.
   PubMed Web of Science ®Google Scholar
• De Sanctis V, Finolezzi E, Osti MF, et al. MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma. Int J Radiat Oncol Biol Phys 2008;72:1154–1160.
   PubMed Web of Science ®Google Scholar
• Zhu YJ, Huang JJ, Xia Y, et al. Primary mediastinal large B-cell lymphoma (PMLBCL) in Chinese patients: clinical characteristics and prognostic factors. Int J Hematol 2011;94:178–184.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Stefoni V, Finolezzi E, et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin Lymphoma Myeloma 2009;9:381–385.
   PubMedGoogle Scholar
• Ahn HK, Kim SJ, Yun J, et al. Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients. Int J Hematol 2010;91:456–463.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Pangalis GA, Katsigiannis A, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist 2012;17:239–249.
   PubMed Web of Science ®Google Scholar
• Avilés A, Neri, Fernández R, et al. Randomized clinical trial to assess the efficacy of radiotherapy in primary mediastinal large B-cell lymphoma. Int J Radiat Oncol Biol Phys 2012;83:1227–1231.
   PubMed Web of Science ®Google Scholar
• Nguyen LN, Ha CS, Hess M, et al. The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum. Int J Radiat Oncol Biol Phys 2000;47:1281–1285.
   PubMed Web of Science ®Google Scholar
• Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Cox JD, Stetz J, Pajak TF. Toxicity of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341–1346.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244–1253.
   PubMed Web of Science ®Google Scholar
• Phan J, Mazloom A, Medeiros LJ, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 2010;28:4170–4176.
   PubMedGoogle Scholar
• Dorth JA, Prosnitz LR, Broadwater G, et al. Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging. Int J Radiat Oncol Biol Phys 2012;84:762–767.
   PubMed Web of Science ®Google Scholar
• Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared to chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21–26.
   PubMed Web of Science ®Google Scholar
• Horning SH, Weller E, Kim KM, et al. Chemotherapy with or without radiotherapy in limited stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004;22:3032–3038.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Kuhnt E, Trümper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;12:1013–1022.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–116.
   PubMed Web of Science ®Google Scholar
• Récher C, Coiffier B, Corinne Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 2011; 378:1858–1867.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Jung SH, Porcu P, et al. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 2012;97:758–765.
   PubMed Web of Science ®Google Scholar
• Dorth JA, Chino JP, Prosnitz LR, et al. The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans. Ann Oncol 2011; 22:405–410.
   PubMed Web of Science ®Google Scholar
• Juweid ME, Cheson BD. Role of positron emission tomography in lymphoma. J Clin Oncol 2005;23:4577–4580.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Tani M, Trisolini R, et al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica 2007;92: 771–777.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Gandolfi L, Broccolin A, et al. Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. Cancer 2011;117:1010–1018.
   PubMed Web of Science ®Google Scholar
• Makis W, Derbekyan V, Hickeson M. Primary mediastinal large B-cell lymphoma (thymic lymphoma) imaged with F-18 FDG PET-CT. Clin Nucl Med 2010;35:421–424.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Martelli M, Magagnoli M, et al. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by 67gallium scan in 50 patients. Blood 1999;94:3289–3293.
   PubMed Web of Science ®Google Scholar